110 related articles for article (PubMed ID: 8292811)
1. Measurement of aspartate carbamoyltransferase activity by high performance liquid chromatography.
Grem JL; Drake JC; Allegra CJ
Anticancer Drugs; 1993 Oct; 4(5):545-54. PubMed ID: 8292811
[TBL] [Abstract][Full Text] [Related]
2. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
Moore EC
Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
[TBL] [Abstract][Full Text] [Related]
3. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
4. In situ properties of Helicobacter pylori aspartate carbamoyltransferase.
Burns BP; Mendz GL; Hazell SL
Arch Biochem Biophys; 1997 Nov; 347(1):119-25. PubMed ID: 9344472
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate.
Grem JL; McAtee N; Drake JC; Steinberg S; Allegra CJ
Adv Exp Med Biol; 1993; 339():119-23. PubMed ID: 8178710
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
7. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA
Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831
[TBL] [Abstract][Full Text] [Related]
8. A 70-amino acid zinc-binding polypeptide fragment from the regulatory chain of aspartate transcarbamoylase causes marked changes in the kinetic mechanism of the catalytic trimer.
Zhou BB; Waldrop GL; Lum L; Schachman HK
Protein Sci; 1994 Jun; 3(6):967-74. PubMed ID: 8069226
[TBL] [Abstract][Full Text] [Related]
9. Regulatory kinetics of wheat-germ aspartate transcarbamoylase. Adaptation of the concerted model to account for complex kinetic effects of uridine 5'-monophosphate.
Yon RJ
Biochem J; 1984 Jul; 221(2):281-7. PubMed ID: 6477473
[TBL] [Abstract][Full Text] [Related]
10. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Monks A; Anderson LW; Strong J; Cysyk RL
J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
[TBL] [Abstract][Full Text] [Related]
11. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
Friedman J; Moore EC; Hall SW; Loo TL
Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
[TBL] [Abstract][Full Text] [Related]
12. Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.
White JC; Hines LH
Biochem Pharmacol; 1984 Nov; 33(22):3645-8. PubMed ID: 6508821
[TBL] [Abstract][Full Text] [Related]
13. N-(Phosphonacetyl)-L-aspartate (PALA): current status.
Rozencweig M; Abele R; Piccart M; Von Hoff DD; Muggia FM
Recent Results Cancer Res; 1980; 74():72-7. PubMed ID: 7444151
[TBL] [Abstract][Full Text] [Related]
14. Overproduction of the first three enzymes of pyrimidine nucleotide biosynthesis in Drosophila cells resistant to N-phosphonacetyl-L-aspartate.
Laval M; Azou Y; Giorgi D; Rosset R
Exp Cell Res; 1986 Apr; 163(2):381-95. PubMed ID: 2869965
[TBL] [Abstract][Full Text] [Related]
15. A single amino acid substitution in the active site of Escherichia coli aspartate transcarbamoylase prevents the allosteric transition.
Stieglitz KA; Pastra-Landis SC; Xia J; Tsuruta H; Kantrowitz ER
J Mol Biol; 2005 Jun; 349(2):413-23. PubMed ID: 15890205
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
[TBL] [Abstract][Full Text] [Related]
17. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
Cooney DA; Karlowicz MG; Cubillan J; Roettger M; Jayaram HN
Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
[TBL] [Abstract][Full Text] [Related]
18. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
Kensler TW; Jayaram HN; Cooney DA
Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
[TBL] [Abstract][Full Text] [Related]
19. Glu-50 in the catalytic chain of Escherichia coli aspartate transcarbamoylase plays a crucial role in the stability of the R quaternary structure.
Tauc P; Keiser RT; Kantrowitz ER; Vachette P
Protein Sci; 1994 Nov; 3(11):1998-2004. PubMed ID: 7703847
[TBL] [Abstract][Full Text] [Related]
20. Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
Ardalan B; Kensler TW; Jayaram HN; Morrison W; Choie DD; Chadwick M; Liss R; Cooney DA
Cancer Res; 1981 Jan; 41(1):150-6. PubMed ID: 7448755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]